Bacteriophages and Diffusion of β-lactamase Genes

We evaluated the presence of various β-lactamase genes within the bacteriophages in sewage. Results showed the occurrence of phage particles carrying sequences of blaOXA-2, blaPSE-1 or blaPSE-4 and blaPSE-type genes. Phages may contribute to the spread of some β-lactamase genes

Cephalosporin-resistant Escherichia coli among Summer Camp Attendees with Salmonellosis

Investigation of an acute gastroenteritis outbreak involving >100 persons at a summer camp in Girona, Spain, in June 2002 led to the detection of Salmonella and extended-spectrum cephalosporin-resistant Escherichia coli (ESCREC). Stool cultures were performed for 22 symptomatic campers, three asymptomatic food handlers, and 10 healthy household members. Of the 22 campers, 19 had Salmonella enterica, 9 had an ESCREC strain carrying an extended-spectrum β-lactamase, and 2 had a second ESCREC strain carrying a plasmidic cephamycinase. Related ESCREC were detected in two (salmonella-negative) asymptomatic food handlers and in none of the healthy household members. Fecal ESCREC and its β-lactamases and plasmids were extensively characterized. Three of the five ESCREC clones were recovered from multiple hosts. The apparent dissemination of ESCREC suggests a food or water vehicle. The observed distribution of resistance plasmids and β-lactamase genes in several clones indicates a high degree of horizontal transfer. Heightened vigilance and increased efforts must be made to discover the reservoirs and vehicles for community dissemination of ESCREC

Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 reduces bacterial translocation in rats treated with carbon tetrachloride

Probiotics can prevent pathological bacterial translocation by modulating intestinal microbiota and improving the gut barrier. The aim was to evaluate the effect of a fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 on bacterial translocation in rats with carbon tetrachloride (CCl)-induced cirrhosis. Sprague-Dawley rats treated with CCl were randomized into a probiotic group that received fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 in drinking water or a water group that received water only. Laparotomy was performed one week after ascites development. We evaluated bacterial translocation, intestinal microbiota, the intestinal barrier and cytokines in mesenteric lymph nodes and serum. Bacterial translocation decreased and gut dysbiosis improved in the probiotic group compared to the water group. The ileal β-defensin-1 concentration was higher and ileal malondialdehyde levels were lower in the probiotic group than in water group. There were no differences between groups in serum cytokines but TNF-α levels in mesenteric lymph nodes were lower in the probiotic group than in the water group. Fermented milk containing Lactobacillus paracasei subsp. paracasei CNCM I-1518 decreases bacterial translocation, gut dysbiosis and ileal oxidative damage and increases ileal β-defensin-1 expression in rats treated with CCl, suggesting an improvement in the intestinal barrier integrity

Guia per a la prevenció i el control de la infecció per Escherichia coli O157:H7 i altres E. coli verotoxígenes

Control d'infeccions; Malalties infeccioses emergents; PrevencióInfection control; Emerging Infectious Diseases; PreventionControl de infecciones; Enfermedades infecciosas emergentes; PrevenciónLa Guia per a la prevenció i el control de la infecció per E. coli O157:H7 i altres E. coli verotoxígenes ha estat elaborada per oferir als professionals sanitaris i de la indústria alimentària una actualització de l’epidemiologia i les mesures de prevenció i control d’aquesta infecció

Effect of Enerplant® biostimulant on ex vitro acclimatization of in vitro propagated sugarcane plants cv. C97-4450

In vitro sugarcane plants (Saccharum spp.) are susceptible to environmental changes in theacclimatization phase, which affects their growth and development. The objective of thiswork was to evaluate the effect of the biostimulant Enerplant® on the survival and growth ofin vitro plants of sugarcane cv. C97-445 inex vitro acclimatization. Three solutions (0.6, 0.8and 1.0 ml l-1) of Enerplant® were evaluated and compared with the biostimulant VIUSID Agro®0.8 ml l-1. Two daily applications were made, the first three days after transplant and thenonce a week. The experiments were carried out in the dry season. The variables evaluatedwere survival at 15 days and morphophysiological at 55 days after transplantation. It wasverified that the application of Enerplant® increases the survival of sugarcanein vitroplantsand improves their growth. Treatment with 0.8 ml l-1 of this biostimulant had the greatest effect onin vitroplant growth underex vitro acclimatization conditions

Efecto del bioestimulante Enerplant® en la aclimatización ex vitro de plantas propagadas in vitro de caña de azúcar cv. C97-445

Las plantas in vitro de caña de azúcar (Saccharum spp.) son susceptibles a los cambios ambientales en la fase de aclimatización lo cual afecta su crecimiento y desarrollo. El presente trabajo tuvo como objetivo evaluar el efecto del bioestimulante Enerplant® en el la supervivencia y el crecimiento de plantas in vitro de caña de azúcar cv. C97-445  en la aclimatización ex vitro. Se evaluaron tres disoluciones (0.6, 0.8 y 1.0 ml l-1) de Enerplant® y se comparó con el bioestimulante VIUSID Agro® 0.8 ml l-1. Se realizaron dos aplicaciones diarias, los primeros tres días y posteriormente una vez por semana. Los experimentos se llevaron a cabo en época de seca. Las variables evaluadas fueron la supervivencia a los 15 días y las morfo-fisiológicas a los 55 días después del trasplante. Se comprobó que la aplicación de Enerplant® incrementa la supervivencia de las plantas in vitro de caña de azúcar y mejora su crecimiento. El tratamiento con 0.8 ml l-1 de este bioestimulante tuvo el mayor efecto en el crecimiento de las plantas in vitro en condiciones de aclimatización ex vitro.Las plantas in vitro de caña de azúcar (Saccharum spp.) son susceptibles a los cambios ambientales en la fase de aclimatización lo cual afecta su crecimiento y desarrollo. El presente trabajo tuvo como objetivo evaluar el efecto del bioestimulante Enerplant® en la supervivencia y el crecimiento de plantas in vitro de caña de azúcar cv. C97-445 en la aclimatización ex vitro. Se evaluaron tres disoluciones (0.6, 0.8 y 1.0 ml l-1) de Enerplant® y se comparó con el bioestimulante VIUSID-Agro® 0.8 ml l-1. Se realizaron dos aplicaciones diarias, los primeros tres días y posteriormente una vez por semana. Los experimentos se llevaron a cabo en época de seca. Las variables evaluadas fueron la supervivencia a los 15 días y las morfofisiológicas a los 55 días después del trasplante. Se comprobó que la aplicación de Enerplant® incrementa la supervivencia de las plantas in vitro de caña de azúcar y mejora su crecimiento. El tratamiento con 0.8 ml l-1 de este bioestimulante tuvo el mayor efecto en el crecimiento de las plantas in vitro en condiciones de aclimatización ex vitro

Guia per a la prevenció i el control de les toxiinfeccions alimentàries

Toxiinfecció alimentària; Medicina preventiva; Seguretat dels alimentsFood poisoning; Preventive medicine; Food safetyToxiinfección alimentaria; Medicina preventiva; Seguridad de los alimentosEn aquesta segona edició de la Guia per a la prevenció i el control de les toxiinfeccions alimentàries es presenta l’etiologia, la patogènia, el tractament i, fonamentalment, la profilaxi de les toxiinfeccions alimentàries més importants i freqüents al nostre medi. Tracta de les normes de declaració, recollida de mostres i mesures de prevenció, i informa sobre les normes de conservació i les mesures de preparació dels aliments per tal d’evitar aquestes malalties

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections

IMPORTANCE The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. OBJECTIVE To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. INTERVENTIONS Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or pa renteral ertapenem for the comparator group after 4 days. MAIN OUTCOMES AND MEASURES The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. RESULTS Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to infinity percentage points; P = .10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI. -infinity to 4.9; percentage points; P = .19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P = .006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P = .01). CONCLUSIONS AND RELEVANCE This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections